Back to top
more

Chugai Pharmaceutical Co. (CHGCY)

(Delayed Data from OTC)

$18.95 USD

18.95
111,478

+0.36 (1.94%)

Updated Jul 22, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (146 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CHGCY

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Chugai Pharmaceutical Co, Ltd Unsponsored ADR falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 5,247 3,874 4,295 3,559 3,064
Receivables 2,274 3,960 3,240 2,382 1,671
Notes Receivable NA 0 0 0 0
Inventories 1,942 2,250 1,900 1,729 1,547
Other Current Assets 239 207 244 179 155
Total Current Assets 9,702 10,291 9,679 7,848 6,437
Net Property & Equipment 2,911 2,890 3,083 2,719 2,351
Investments & Advances NA 14 22 27 27
Other Non-Current Assets NA 0 0 0 0
Deferred Charges 511 542 524 455 393
Intangibles 141 194 200 224 217
Deposits & Other Assets 381 379 373 263 228
Total Assets 13,721 14,397 14,002 11,614 9,742
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable NA 0 0 0 0
Accounts Payable 799 1,616 1,386 944 714
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 0 0 0 0
Income Taxes Payable 290 759 785 594 378
Other Current Liabilities 958 888 808 682 557
Total Current Liabilities 2,046 3,263 2,980 2,219 1,649
Mortgages NA 0 0 0 0
Deferred Taxes/Income 63 80 96 108 151
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities 70 87 116 75 85
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities 2,179 3,429 3,191 2,402 1,885
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock NA 0 0 0 0
Common Stock (Par) 520 564 666 688 672
Capital Surplus 492 530 621 635 617
Retained Earnings 10,570 9,959 9,592 7,981 6,643
Other Equity -41 -84 -68 -93 -75
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity 11,542 10,968 10,811 9,212 7,857
Total Liabilities & Shareholder's Equity 13,721 14,397 14,002 11,614 9,742
Total Common Equity 111,541 10,968 10,811 9,212 7,857
Shares Outstanding 3,289.90 3,289.90 NA NA NA
Book Value Per Share 33.90 3.33 -0.11 -0.09 -0.08

Fiscal Year End for Chugai Pharmaceutical Co, Ltd Unsponsored ADR falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 -99,999 5,247 4,269 -99,999
Receivables NA NA 2,274 2,188 NA
Notes Receivable NA NA NA NA NA
Inventories NA NA 1,942 1,915 NA
Other Current Assets NA NA 239 301 NA
Total Current Assets NA NA 9,702 8,673 NA
Net Property & Equipment NA NA 2,911 2,802 NA
Investments & Advances NA NA NA NA NA
Other Non-Current Assets NA NA NA NA NA
Deferred Charges NA NA 511 486 NA
Intangibles NA NA 141 138 NA
Deposits & Other Assets NA NA 381 362 NA
Total Assets NA NA 13,721 12,542 NA
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA NA NA NA NA
Accounts Payable NA NA 799 775 NA
Current Portion Long-Term Debt NA NA NA NA NA
Current Portion Capital Leases NA NA NA NA NA
Accrued Expenses NA NA NA NA NA
Income Taxes Payable NA NA 290 81 NA
Other Current Liabilities NA NA 958 966 NA
Total Current Liabilities NA NA 2,046 1,822 NA
Mortgages NA NA NA NA NA
Deferred Taxes/Income NA NA 63 55 NA
Convertible Debt NA NA NA NA NA
Long-Term Debt NA NA NA NA NA
Non-Current Capital Leases NA NA NA NA NA
Other Non-Current Liabilities NA 70 73 NA
Minority Interest (Liabilities) NA NA NA NA NA
Total Liabilities NA NA 2,179 1,950 NA
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA NA NA NA NA
Common Stock (Par) NA NA 520 505 NA
Capital Surplus NA NA 492 478 NA
Retained Earnings NA NA 10,570 9,630 NA
Other Equity NA NA -41 -21 NA
Treasury Stock NA NA NA NA NA
Total Shareholder's Equity NA NA 11,542 10,591 NA
Total Liabilities & Shareholder's Equity NA NA 13,721 12,542 NA
Total Common Equity 0 0 111,541 110,590 0
Shares Outstanding 3,289.90 3,289.90 3,289.90 3,289.90 3,289.90
Book Value Per Share 0.00 0.00 33.90 33.62 0.00